Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Immunoglobulin (pH4) for Intravenous Injection in Primary Immune Thrombocytopenia
CTR20231083Phase 3Completed
- Sponsor
- Danxia Biological Pharmaceutical
- Start
- Apr 2023
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of human immunoglobulin (pH 4) for intravenous injection in immune thrombocytopenia (ITP), sponsored by Danxia Biological Pharmaceutical. Primary endpoint: Primary response rate at day 7. Started Apr 2023; status: completed.
02
Drugs
human immunoglobulin (pH 4) for intravenous injection
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20231083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231083.